What caused the IHL.AX stock drop on 20 Jan 2026?

The intra-day decline to **A$0.041** was driven by heavy volume and cross-market flows. There was no single confirmed catalyst; traders cited ADR quotes and speculative repositioning. Clinical updates would be required for a sustained fundamental move.

Is IHL.AX stock a buy after the volume spike?

Meyka rates IHL.AX **B (HOLD)**. A buy decision should weigh clinical milestones, cash runway and dilution risk. The stock is high volatility; active traders may exploit liquidity, while longer-term investors should await clearer data.

What are the key valuation metrics for IHL.AX stock?

Key metrics: **price A$0.041**, market cap **A$14,255,927.00**, EPS **-1.30**, P/S **14.06**, P/B **0.75**, current ratio **9.02**. These show a small cash-rich developer with negative earnings.

What price does Meyka forecast for IHL.AX stock?

Meyka AI's forecast model projects **A$0.090** in 12 months for IHL.AX stock, an implied upside of **119.51%** from A$0.041. Forecasts are model-based projections and not guarantees.

AU Stocks

Incannex A$0.041 (IHL.AX ASX) 20 Jan 2026 after hours: heavy volume suggests shift

ByHuzaifa Zahoor January 20, 2026

We saw IHL.AX stock trade at A$0.041 in after hours on 20 Jan 2026, down 10.87% on heavy activity. Volume hit 61,360,016 shares, nearly ten times average daily flow, making Incannex Healthcare Limited one of the most active ASX names tonight. The move follows a volatile session where the stock opened at A$0.047 and reached an intraday high of A$0.051. We track how volume, valuation and clinical news connect to price action for Australian investors trading in AUD on the ASX.